Surgical and Oncologic Outcomes of Primary Tumor Resection in Patients with Small Intestinal Neuroendocrine Tumors: Results from a Single-Center Series Over a 15-Year Period

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2024 Dec 3

PMID 39627636

Authors

Maria Danieli

Uberto Fumagalli Romario

Davide Radice

Simonetta Pozzi

Francesca Spada

Luigi Funicelli

Nicola Fazio

Emilio Bertani

Affiliations

Soon will be listed here.

Abstract

Background: The role of prophylactic primary tumor resection (PTR) in patients with small intestinal neuroendocrine tumors (SI-NETs) and unresectable liver metastases is a matter of debate.

Objective: We aimed to evaluate outcomes in patients with SI-NETs who underwent PTR, according to the presence of metastasis and symptoms from primary.

Material And Methods: Data from patients who underwent PTR for SI-NETs from a single referral center (2007-2023) were prospectively collected. Patients were divided into three groups: non-metastatic (M0) and metastatic with primary tumor-related symptoms (MS) or metastatic asymptomatic (MA). Kaplan-Meier curves for overall survival (OS) and event-free survival (EFS) were generated and compared by group. Univariate and multivariable Cox regression analyses were performed to assess the significance of risk factors.

Results: Of 147 patients, 53 were M0, 23 were MS, and 71 were MA. Median follow-up was 26 months. The 5- and 10-year OS estimates were 100% and 100% in M0 patients, 82 and 21% in MS patients, and 89 and 80% in MA patients, respectively (p < 0.001). Median EFS was 91 months overall and 43,126 months and not reached for the MS, MA, and M0 groups, respectively (p < 0.001). In multivariable analysis, MS (hazard ratio [HR] 3.92, 95% confidence interval [CI] 1.71-9.52), functioning tumors (HR 1.98, 95% CI 1.03-3.81), and G2 grade (HR 3.20, 95% CI 1.64-6.85) were associated with a shorter EFS.

Conclusions: In this large retrospective series, the MS group had a significantly worse OS and EFS compared with M0 and MA. This finding suggests that prophylactic PTR might benefit SI-NET patients with unresectable liver metastases, as symptom development could impair long-term prognosis after surgery.

Citing Articles

ASO Author Reflections: Primary Tumor Resection in Metastatic Small Intestinal Neuroendocrine Tumors: A Step Toward Standardized Management?.

Danieli M, Bertani E Ann Surg Oncol. 2024; 32(3):2185-2186.

PMID: 39722085 DOI: 10.1245/s10434-024-16718-3.

References

Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y . Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017; 3(10):1335-1342. PMC: 5824320. DOI: 10.1001/jamaoncol.2017.0589. View

Bilimoria K, Bentrem D, Wayne J, Ko C, Bennett C, Talamonti M . Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2008; 249(1):63-71. DOI: 10.1097/SLA.0b013e31818e4641. View

Ter-Minassian M, Chan J, Hooshmand S, Brais L, Daskalova A, Heafield R . Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. Endocr Relat Cancer. 2013; 20(2):187-96. PMC: 3739696. DOI: 10.1530/ERC-12-0340. View

Landerholm K, Falkmer S, Jarhult J . Epidemiology of small bowel carcinoids in a defined population. World J Surg. 2010; 34(7):1500-5. DOI: 10.1007/s00268-010-0519-z. View

Gangi A, Howe J . The Landmark Series: Neuroendocrine Tumor Liver Metastases. Ann Surg Oncol. 2020; 27(9):3270-3280. PMC: 7415723. DOI: 10.1245/s10434-020-08787-x. View

Scott A, Breheny P, Keck K, Bellizzi A, Dillon J, ODorisio T . Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). Surgery. 2018; 165(1):166-175. PMC: 6637412. DOI: 10.1016/j.surg.2018.04.070. View

Sarmiento J, Heywood G, Rubin J, Ilstrup D, Nagorney D, Que F . Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003; 197(1):29-37. DOI: 10.1016/S1072-7515(03)00230-8. View

Mayo S, Jong M, Pulitano C, Clary B, Reddy S, Clark Gamblin T . Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010; 17(12):3129-36. DOI: 10.1245/s10434-010-1154-5. View

Partelli S, Bartsch D, Capdevila J, Chen J, Knigge U, Niederle B . ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017; 105(3):255-265. DOI: 10.1159/000464292. View

10.

Nigam A, Li J, Fiasconaro M, Lin S, Capanu M, Kleiman D . Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors. Ann Surg Oncol. 2023; 31(4):2337-2348. DOI: 10.1245/s10434-023-14637-3. View

11.

Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D . Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer. 2009; 16(3):885-94. DOI: 10.1677/ERC-09-0042. View

12.

Lewis A, Raoof M, Ituarte P, Williams J, Melstrom L, Li D . Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. Ann Surg. 2018; 270(6):1131-1137. DOI: 10.1097/SLA.0000000000002809. View

13.

Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K . Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg. 2002; 26(8):991-7. DOI: 10.1007/s00268-002-6630-z. View

14.

Bennett S, Coburn N, Law C, Mahar A, Zhao H, Singh S . Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases: A Propensity-score Matched Comparative Population-based Analysis. Ann Surg. 2020; 276(5):e450-e458. DOI: 10.1097/SLA.0000000000004647. View

15.

Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A . European Neuroendocrine Tumor Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J Neuroendocrinol. 2022; 34(7):e13146. PMC: 9539661. DOI: 10.1111/jne.13146. View

16.

Lardiere-Deguelte S, de Mestier L, Appere F, Vullierme M, Zappa M, Hoeffel C . Toward a Preoperative Classification of Lymph Node Metastases in Patients with Small Intestinal Neuroendocrine Tumors in the Era of Intestinal-Sparing Surgery. Neuroendocrinology. 2015; 103(5):552-9. DOI: 10.1159/000441423. View

17.

Bertani E, Zugni F, Radice D, Spada F, Bonomo G, Romario U . Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors. Updates Surg. 2022; 74(5):1697-1704. DOI: 10.1007/s13304-022-01251-3. View

18.

Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Fave G, Falconi M . Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg. 2012; 99(11):1480-6. DOI: 10.1002/bjs.8842. View

19.

Hayes A, Davar J, Caplin M . Carcinoid Heart Disease: A Review. Endocrinol Metab Clin North Am. 2018; 47(3):671-682. DOI: 10.1016/j.ecl.2018.04.012. View

20.

Kaemmerer D, Twrznik M, Kulkarni H, Horsch D, Sehner S, Baum R . Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms. Ann Surg. 2020; 274(1):e45-e53. DOI: 10.1097/SLA.0000000000003237. View